Trial Profile
A Phase III Randomized Double Blind Placebo Controlled Trial of CM-AT in Children With Autism.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs CM 4612 (Primary)
- Indications Autistic disorder
- Focus Registrational; Therapeutic Use
- 04 Nov 2013 Curemark submitted an NDA for CM 4612 to the US FDA.
- 06 Aug 2012 FDA approves direct enrolment into an open label extension. Not sure how this relates to the extension info that was already in here
- 30 Sep 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov (Parent trial: NCT00881452).